Details for Patent: 6,323,205

Title:	Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
Abstract:	Preliminary clinical studies in humans have now been done which show both the efficacy of 10-propargyl-10dAM and a preferred dosage schedule for such treatments. In addition, it has now been determined that combinations of 10-propargyl-10-deazaaminopterin (preferably highly purified forms, substantially free of 10-deazaaminopterin) with taxols exhibit synergistic effectiveness in the treatment of tumors. 10-propargyl-10-deazaaminopterin and a taxol in therapeutically effective amounts can be administered concurrently, one right after the other, or with a period of time in between.
Inventor(s):	Sirotnak; Francis M. (New York, NY), Piper; James R. (Birmingham, AL), DeGraw; Joseph I. (Missoula, MT), Colwell; William T. (Menlo Park, CA)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY) SRI International (Menlo Park, CA) Southern Research Institute (Birmingham, AL)
Filing Date:	Feb 17, 2000
Application Number:	09/505,571
Claims:	1. A method for treatment of tumors comprising administering to a patient diagnosed as having a tumor therapeutically effective amounts of 10-propargyl-10-deazaaminopterin and a taxane, wherein the tumors are selected from the group consisting of mammary tumors, lung cancer, prostate cancer and leukemias. 2. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin. 3. The method of claim 1, wherein the tumor is a solid tumor. 4. The method of claim 3, wherein the tumor is a mammary tumor. 5. The method of claim 3, wherein the tumor is a lung tumor. 6. The method of claim 3, wherein the tumor is a prostate tumor. 7. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered biweekly. 8. The method of claim 1, wherein the taxane is administered immediately following the 10-propargyl-10-deazaaminopterin. 9. The method of claim 8, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin. 10. The method of claim 8, wherein the tumor is a solid tumor. 11. The method of claim 10, wherein the tumor is a mammary tumor. 12. The method of claim 10, wherein the tumor is a lung tumor. 13. The method of claim 10, wherein the tumor is a prostate tumor. 14. The method of claim 8, wherein the 10-propargyl-10-deazaaminopterin is administered biweekly. 15. A method for treatment of tumors comprising administering to a human patient diagnosed as having a tumor a therapeutically effective amount of 10-propargyl-10-deazaaminopterin, wherein the 10-propargyl-10-deazaaminopterin is administered in biweekly doses, and wherein the tumor is selected from the group consisting of mammary tumors, lung cancer, prostate cancer and leukemias. 16. The method of claim 15, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of 150 mg/m.sup.2 /biweekly dose. 17. The method of claim 15, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin. 18. A method for treatment of tumors comprising administering to a patient diagnosed as having a tumor therapeutically effective amounts of 10-propargyl-10-deazaaminopterin and a taxane, wherein the tumors are selected from among tumors expressing folyl polyglutamate synthetase and wherein the folyl polyglutamate synthetase is effective to catalyze the polyglutamylation of the 10-propargyl-10-deazaaminopterin.